Name: Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Scenario analyses
Published: 2026-09-21T22:15:09-04:00

Economic information and modeling report Budget impact model Results

Scenario analyses

1 evidence topic · 3 sources

Budget impact model of tovecimig: scenario analyses

No evidence found.

Sensitivity and scenario analyses in economic evaluations of advanced biliary tract cancer

“Sensitivity analysis showed that the analysis was most sensitive to the price of durvalumab.” (opens the source at this quote in a new tab)

“In China and the US, the ICER for pembrolizumab plus chemotherapy compared with that of chemotherapy alone was $535,405/QALY and $1,118,607/QALY.” (opens the source at this quote in a new tab)
“The results of the subgroup analysis indicate that better survival properties subgroups were more likely to be cost-effective, although pembrolizumab plus chemotherapy may not be cost-effective for all subgroups.” (opens the source at this quote in a new tab)

“PSA showed price cuts (~50–60%) needed” (opens the source at this quote in a new tab)
“A price reduction of at least approximately 50% improved cost-effectiveness results.” (opens the source at this quote in a new tab)
“In the economic models, the cost of the immune-checkpoint inhibitor component was repeatedly identified as a major driver of unfavorable cost-effectiveness results.” (opens the source at this quote in a new tab)